Department of Community Health and Prevention, Drexel University School of Public Health, Philadelphia, PA, USA.
BMC Infect Dis. 2014 Jan 9;14:16. doi: 10.1186/1471-2334-14-16.
A limitation of both culture-based and molecular methods of screening for staphylococcal infection is that current tests determine only the presence or absence of colonization with no information on the colonizing strain type. A technique that couples polymerase chain reaction to mass spectrometry (PCR/ESI-MS) has recently been developed and an assay validated to identify and genotype S. aureus and coagulase-negative staphylococci (CoNS).
This study was conducted to determine the rates, risk factors, and molecular genotypes of colonizing Staphylococcus aureus in adult patients presenting to an inner-city academic emergency department. Participants completed a structured questionnaire to assess hospital and community risks for infection with methicillin-resistant S. aureus (MRSA). Nasal swabs were analyzed by PCR/ESI-MS to identify and genotype S. aureus and CoNS.
Of 200 patients evaluated, 59 were colonized with S. aureus; 27 of these were methicillin-resistant strains. Twenty-four of the 59 S. aureus carriers were co-colonized with a CoNS and 140 of the 200 patients were colonized exclusively with CoNS. The molecular genotypes of the 59 S. aureus strains were diverse; 21 unique molecular genotypes belonging to seven major clonal complexes were identified. Eighty-five of 200 patients carried strains with high-level mupirocin resistance. Of these eighty-five participants, 4 were colonized exclusively with S. aureus, 16 were co-colonized with S. aureus and CoNS, and 65 were colonized exclusively with CoNS.
The prevalence of S. aureus and methicillin-resistant S. aureus colonization in a random sample of patients seeking care in Emergency Department was 29.5% and 13.5%, respectively. A substantial fraction of the S. aureus-colonized patients were co-colonized with CoNS and high-level mupirocin-resistant CoNS. Determining the molecular genotype of S. aureus during intake screening may prove valuable in the future if certain molecular genotypes become associated with increased infection risk.
基于培养和分子方法筛选葡萄球菌感染的一个局限性在于,目前的检测只能确定定植的存在或不存在,而不能提供定植菌株类型的信息。一种将聚合酶链反应与质谱法(PCR/ESI-MS)相结合的技术最近已经开发出来,并验证了一种用于鉴定和基因分型金黄色葡萄球菌和凝固酶阴性葡萄球菌(CoNS)的检测方法。
本研究旨在确定在城市内一所学术急诊部门就诊的成年患者中定植金黄色葡萄球菌的发生率、危险因素和分子基因型。参与者完成了一份评估耐甲氧西林金黄色葡萄球菌(MRSA)医院和社区感染风险的结构化问卷。通过 PCR/ESI-MS 分析鼻拭子,以鉴定和基因分型金黄色葡萄球菌和 CoNS。
在评估的 200 名患者中,有 59 名患者定植了金黄色葡萄球菌;其中 27 株为耐甲氧西林菌株。59 名金黄色葡萄球菌携带者中有 24 名与凝固酶阴性葡萄球菌共同定植,200 名患者中有 140 名仅定植凝固酶阴性葡萄球菌。59 株金黄色葡萄球菌的分子基因型多种多样;鉴定出属于七个主要克隆复合体的 21 个独特的分子基因型。200 名患者中有 85 名携带高水平莫匹罗星耐药菌。在这 85 名参与者中,有 4 名仅定植金黄色葡萄球菌,16 名与金黄色葡萄球菌和凝固酶阴性葡萄球菌共同定植,65 名仅定植凝固酶阴性葡萄球菌。
在急诊就诊的患者随机样本中,金黄色葡萄球菌和耐甲氧西林金黄色葡萄球菌定植的患病率分别为 29.5%和 13.5%。金黄色葡萄球菌定植患者的很大一部分与凝固酶阴性葡萄球菌共同定植,并且对高水平莫匹罗星耐药的凝固酶阴性葡萄球菌。如果某些分子基因型与感染风险增加相关,那么在入院筛查时确定金黄色葡萄球菌的分子基因型可能在未来具有重要价值。